INTEGRATED BIOPHARMA INC
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 11, 2026
INBPStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. EXHIBITS
(a) Exhibits
Exhibit
Number
| 31.1 | Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer. | |
| 31.2 | Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer. | |
| 32.1 | Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer. | |
| 32.2 | Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer. | |
| 101.INS*** | Inline XBRL Instance | Furnished herewith |
| 101.SCH*** | Inline XBRL Taxonomy Extension Schema | Furnished herewith |
| 101.CAL*** | Inline XBRL Taxonomy Extension Calculation | Furnished herewith |
| 101.DEF*** | Inline XBRL Taxonomy Extension Definition | Furnished herewith |
| 101.LAB*** | Inline XBRL Taxonomy Extension Labels | Furnished herewith |
| 101.PRE*** | Inline XBRL Taxonomy Extension Presentation | Furnished herewith |
| 104 | Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.
| Date: February 11, 2026 | By: /s/ Christina Kay |
|---|---|
| Christina Kay, | |
| Co-Chief Executive Officer | |
| Date: February 11, 2026 | By: /s/ Riva Sheppard |
| Riva Sheppard, | |
| Co-Chief Executive Officer | |
| By: /s/ Dina L. Masi | |
| Date: February 11, 2026 | Dina L. Masi, |
| Chief Financial Officer & Senior Vice President |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.